Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)

Conditions

• Dengue

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• Emetine Hydrochloride 6mg — DRUG
  To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.
• Placebo — DRUG
  Participant take a placebo for 10 consecutive days.
• Emetine Hydrochloride 12mg — DRUG
  To administer Emetine Hydrochloride 12mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.

Study Details

The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1. Does emetine reduce 28-day mortality or progression to severe dengue (severe plasma leakage, severe bleeding, or severe organ involvement)? 2. What are the safety outcomes of emetine, including serious adverse events and toxicities? Participants will be asked to: 1. Take either 6mg emetine, 12mg emetine, or a placebo pill for 7 consecutive days as part of the treatment regimen. 2. Have blood samples taken for at least 5 days to monitor viral load, inflammatory markers, and safety parameters. 3. Be monitored by healthcare staff for daily vital signs and symptoms for clinical assessments for 28 days.

Key Dates

Start date

Jun 25, 2026

Status verified

Jun 2026

Primary completion

Mar 1, 2029

Completion

May 3, 2029

Study Design

Enrollment

600 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Emetine 6 mg
  Participants take 6mg Emetine pill for 10 consecutive days
• Active Comparator: Emetine 12 mg
  Participants take 12mg Emetine pill for 10 consecutive days
• Placebo Comparator: Placebo
  Participant take a placebo for 10 consecutive days

Primary Outcome Measure

Evaluate effectiveness of emetine in dengue patients assessed by 28-day mortality or progression [ Time Frame: 28 days ]

Central Contacts

• Kunchok Dorjee, MBBS, PhD
  4105027135
  [email protected]

Locations (1)

Find similar trials in Baltimore, MD